Rivastigmine improves dual-task gait velocity in patients with Alzheimer’s disease

BACKGROUND: Gait impairments are common in patients with Alzheimer’s disease. Cholinesterase inhibitors are used to treat the symptoms of patients with Alzheimer’s disease, but they have not been shown to reduce the severity of Alzheimer’s disease-related gait disorders. METHODS: This was a prospect...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimura, Hideki, Saiko, Aiba, Hayashi, Akito, Hattori, Nobutaka, Urabe, Takao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874473/
https://www.ncbi.nlm.nih.gov/pubmed/33568083
http://dx.doi.org/10.1186/s12883-021-02098-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874473/
https://www.ncbi.nlm.nih.gov/pubmed/33568083
http://dx.doi.org/10.1186/s12883-021-02098-8

Ejemplares similares